Immunomodulatory Properties of Kappa Opioids and Synthetic Cannabinoids in HIV-1 Neuropathogenesis

  title={Immunomodulatory Properties of Kappa Opioids and Synthetic Cannabinoids in HIV-1 Neuropathogenesis},
  author={Shuxian Hu and Wen S. Sheng and Robert Bryan Rock},
  journal={Journal of Neuroimmune Pharmacology},
Anti-retroviral therapy (ART) has had a tremendous impact on the clinical outcomes of HIV-1 infected individuals. While ART has produced many tangible benefits, chronic, long-term consequences of HIV infection have grown in importance. HIV-1-associated neurocognitive disorder (HAND) represents a collection of neurological syndromes that have a wide range of functional cognitive impairments. HAND remains a serious threat to AIDS patients, and there currently remains no specific therapy for the… 

Development of Novel Quinoxaline-Based κ-Opioid Receptor Agonists for the Treatment of Neuroinflammation.

In the EAE model, the secondary amine 12 and the triazole 14 were able to ameliorate disease severity and to delay disease onset by blocking effector T cell activation, and the beneficial effects were mediated via signaling through KOR because off-target effects were excluded by using KOR-deficient mouse mutants.

Cannabinoid Type-2 Receptor Agonist, JWH133 May Be a Possible Candidate for Targeting Infection, Inflammation, and Immunity in COVID-19

It is proposed that JWH133, a selective, full functional agonist of the CB2 receptor, has been extensively studied for its potent anti-inflammatory, antiviral, and immunomodulatory properties and should be investigated in preclinical and clinical studies for its potential as an agent or adjuvant with other agents in COVID-19.

Attenuation of HIV‐1 replication in macrophages by cannabinoid receptor 2 agonists

It is reported that CB2 agonists can also act as immunomodulators on HIV‐1‐infected macrophages and that prevention of viral entry is not a central mechanism for CB2‐mediated suppression in viral replication.

Opioid and neuroHIV Comorbidity – Current and Future Perspectives

What is currently known about mechanisms underlying opioid interactions with HIV is explored, with emphasis on individual HIV-1-expressed gene products at the molecular, cellular and systems levels, and topics that need to be considered in the future to better understand the unique contributions of opioids to the pathophysiology of neuroHIV.

Opioid System and Alzheimer’s Disease

The opioid system is potentially related to AD pathology and may be a very attractive drug target for novel pharmacotherapies of AD.

Opioids and Viral Infections: A Double-Edged Sword

This review supports the emerging concept that opioids and their receptors have both favorable and unfavorable effects on viral disease, depending on the type of virus.

Opioid κ Receptors as a Molecular Target for the Creation of a New Generation of Analgesic Drugs

This review provides a brief description of the main structural and functional features of the κ opioid receptor, along with the properties of its agonists and the potential for using these in



Immunoregulation of a CB2 Receptor Agonist in a Murine Model of NeuroAIDS

The results support the notion that CB2 receptor agonists may be a viable therapeutic candidate for HAND and suggest that the endocannabinoid system modulates neuroimmunity and as such neuronal and glial functions.

U50488 inhibits HIV-1 expression in acutely infected monocyte-derived macrophages.

Cannabinoids as therapeutic agents for ablating neuroinflammatory disease.

The cannabinoid-cannabinoid receptor system may prove therapeutically manageable in ablating neuropathogenic disorders such as Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, HIV encephalitis, closed head injury, and granulomatous amebic encephalopathy.

Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV‐1 Tat exposure in vitro

The results imply that opiates can enhance the cytotoxicity of HIV‐1 Tat through direct actions on glial precursors and/or astroglia, suggesting novel cellular targets for HIV–opiate interactions.

κ-Opioid Receptor Ligands Inhibit Cocaine-Induced HIV-1 Expression in Microglial Cells

The findings of this study suggest that in addition to its neurotoxic effects, cocaine could foster development of HAD by potentiating viral expression in the brain and that this phenomenon is inhibited by KOR ligands.

Cannabinoids Inhibit HIV-1 Gp120-Mediated Insults in Brain Microvascular Endothelial Cells1

It is shown for the first time that cannabinoid agonists inhibited HIV-1 Gp120-induced calcium influx mediated by substance P and significantly decreased the permeability of HBMEC as well as prevented tight junction protein down-regulation of ZO-1, claudin-5, and JAM-1 in H BMEC.

Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation

Mechanistic insight is provided into beneficial effects provided by cannabinoid receptor CB2 modulation in neurodegenerative diseases, particularly AD.

Mechanisms of Neuroimmunity and Neurodegeneration Associated with HIV-1 Infection and AIDS

Recently uncovered pathologic neuroimmune and degenerative mechanisms contributing to neuronal damage induced by HIV-1 are addressed and experimental and potentially future therapeutic approaches are discussed.